---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021658"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:06:05.631180+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vanda Q1 revenue $47.5M, net loss $4.1M; Fanapt bipolar approval, PONVORY launch in Q3

## Summary
- Net loss $4.1M (diluted EPS -$0.07) vs net income $3.3M ($0.06) in Q1 2023; revenue $47.5M, -24% YoY.
- Cash increased $5.9M to $394.1M; Fanapt approved for acute bipolar I disorder, launch Q3 2024.
- PONVORY commercial launch in multiple sclerosis expected Q3 2024; tradipitant NDA for gastroparesis under FDA review with PDUFA Sept 18, 2024.
- Milsaperidone NDA for schizophrenia and bipolar expected early-2025; tradipitant motion sickness Phase III results Q2 2024.
- No FY 2024 guidance given due to HETLIOZ generic competition and upcoming launches.

## SEC filing metadata
- accession: 0001628280-24-021658
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828024021658/0001628280-24-021658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828024021658/vnda-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021658
- JSON: https://secwatch.observer/filing/0001628280-24-021658.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021658.txt

## Key facts
- Earnings Releases
  Vanda Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $47.5 million, net income $(4.1) million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $47.5 million
  - Net income: $(4.1) million
  - Result: reported results
  source text: Financial Highlights • Total net product sales from Fanapt ® , HETLIOZ ® and PONVORY ® were $47.5 million in the first quarter of 2024, a 24% decrease compared to $62.5 million in the first quarter of 2023, and a 5% increase compared to $45.3 million in the fourth quarter of 2023. • Fanapt ® net product sales were $20.6 million in the first quarter of 2024, a 10% decrease compared to $22.9 million in the first quarter of 2023, and a 9% decrease compared to $22.6 million in the fourth quarter of 2023. • HETLIOZ ® net product sales were $20.1 million in the first quarter of 2024, a 49% decrease compared to $39.6 million in the first quarter of 2023, and a 5% decrease compared to $21.1 million in the fourth quarter of 2023. The decrease relative to the first quarter of 2023 was the result of continued generic competition in the U.S. • PONVORY ® net product sales were $6.8 million in the first quarter of 2024. The acquisition of PONVORY ® from Actelion Pharmaceuticals Ltd. (Janssen), a Joh
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828024021658/0001628280-24-021658-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.